SG11201907738UA - Ranking system for immunogenic cancer-specific epitopes - Google Patents

Ranking system for immunogenic cancer-specific epitopes

Info

Publication number
SG11201907738UA
SG11201907738UA SG11201907738UA SG11201907738UA SG11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA SG 11201907738U A SG11201907738U A SG 11201907738UA
Authority
SG
Singapore
Prior art keywords
international
dist
rule
taipei city
epitopes
Prior art date
Application number
SG11201907738UA
Other languages
English (en)
Inventor
Yang Pei-Jia
Jen-Hao Cheng
Ying-Ja Chen
Shu-Jen Chen
Hua-Chien Chen
Original Assignee
Pei Jia Yang
Cheng Jen Hao
Chen Ying Ja
Chen Shu Jen
Chen Hua Chien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pei Jia Yang, Cheng Jen Hao, Chen Ying Ja, Chen Shu Jen, Chen Hua Chien filed Critical Pei Jia Yang
Publication of SG11201907738UA publication Critical patent/SG11201907738UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
SG11201907738UA 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes SG11201907738UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479320P 2017-03-31 2017-03-31
PCT/US2018/025597 WO2018183980A2 (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Publications (1)

Publication Number Publication Date
SG11201907738UA true SG11201907738UA (en) 2019-09-27

Family

ID=63676910

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907738UA SG11201907738UA (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Country Status (7)

Country Link
US (1) US11485784B2 (https=)
EP (1) EP3600340A4 (https=)
JP (1) JP7155470B2 (https=)
CN (1) CN110799196B (https=)
SG (1) SG11201907738UA (https=)
TW (1) TWI672503B (https=)
WO (1) WO2018183980A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970865T3 (es) * 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
BR112021005353A2 (pt) * 2018-11-21 2021-06-15 Nec Corporation método e sistema de direcionamento de epitopos para imunoterapia baseada em neoantígeno
KR20240091046A (ko) * 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
EP3931834A1 (en) 2019-02-28 2022-01-05 Universiteit Antwerpen Method for determining responsiveness to an epitope
WO2020223361A1 (en) * 2019-04-30 2020-11-05 Memorial Sloan Kettering Cancer Center System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens
WO2021216787A1 (en) * 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Methods and systems for analysis of receptor interaction
WO2022170067A1 (en) * 2021-02-05 2022-08-11 Amazon Technologies, Inc. Ranking neoantigens for personalized cancer vaccine
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
CN118302816A (zh) * 2021-09-28 2024-07-05 行动基因(智财)有限公司 甲基化生物标记选择装置及方法
WO2025217519A1 (en) * 2024-04-12 2025-10-16 Foundation Medicine, Inc. Clonal neoantigen burden as a biomarker of immunotherapy response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CN113791220A (zh) 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN107704727B (zh) 2017-11-03 2020-01-31 杭州风起智能科技有限公司 基于肿瘤新抗原特征值的新抗原活性预测和排序方法

Also Published As

Publication number Publication date
US20210284738A1 (en) 2021-09-16
US11485784B2 (en) 2022-11-01
TWI672503B (zh) 2019-09-21
CN110799196A (zh) 2020-02-14
CN110799196B (zh) 2024-02-13
WO2018183980A3 (en) 2018-12-20
WO2018183980A2 (en) 2018-10-04
EP3600340A2 (en) 2020-02-05
JP2020518083A (ja) 2020-06-18
TW201903411A (zh) 2019-01-16
EP3600340A4 (en) 2021-01-20
JP7155470B2 (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
SG11201907738UA (en) Ranking system for immunogenic cancer-specific epitopes
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909949XA (en) Targeted immunotolerance
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808797XA (en) T cell receptors
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201811559WA (en) Cancer treatment combinations
SG11201804704PA (en) Compositions and methods for decreasing tau expression